Liu Xiaobo, Panthagani Praneetha, Gutierrez Ana G, Vega Arlette, Shaik Abdul A, Aguilera Monica G, Sanchez Jordan N, Willms Joshua O, Backus Brittany, Blough Bruce, Pauli Elliott, Reid Ted W, Benton Thomas, Bailoo Jeremy D, Bergeson Susan E
Department of Pharmacology & Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Department of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Alcohol Treat Q. 2024;42(4):393-403. doi: 10.1080/07347324.2024.2355931. Epub 2024 May 30.
Three medications are FDA approved in the US for treatment of Alcohol Use Disorder (AUD), and a few others are used off-label. Patient compliance and efficacy in the broader population are major hurdles for current AUD medications. As a consequence, there is an urgent need for improved pharmacotherapeutics to complement behavioral approaches. Here, we report pilot testing of a minocycline analog, 10-butylether minocycline (BEM, 10 mg/kg p.o.), in two female minipigs with free-choice drinking to intoxication for nearly two and a half years. Each pig met DSM-5 criteria for diagnosis of severe AUD, and BEM reduced both alcohol intake and preference. BEM is currently undergoing testing for approval as an Investigational New Drug by the FDA for AUD treatment.
在美国,有三种药物被美国食品药品监督管理局(FDA)批准用于治疗酒精使用障碍(AUD),还有其他一些药物被用于非标签用途。在更广泛的人群中,患者的依从性和疗效是当前治疗AUD药物的主要障碍。因此,迫切需要改进药物治疗方法以补充行为治疗方法。在此,我们报告了对一种米诺环素类似物10-丁基醚米诺环素(BEM,口服10毫克/千克)在两只雌性小型猪中的初步试验,这两只小型猪可以自由选择饮水直至醉酒,试验持续了近两年半。每只猪都符合《精神疾病诊断与统计手册》第5版(DSM-5)中重度AUD的诊断标准,并且BEM减少了酒精摄入量和偏好。BEM目前正在接受FDA的测试,以作为一种用于治疗AUD的研究性新药获得批准。